帯状疱疹後卒中リスク 6ヶ月は増加、帯状疱疹ワクチン・抗ウィルス薬による減少効果可能性

帯状疱疹後卒中リスクを、英国内データ　6584名 で検討



Risk of Stroke Following Herpes Zoster: A Self-Controlled Case-Series Study Sinéad M. Langana, et. al.
Clin Infect Dis. (2014) doi: 10.1093/cid/ciu098 First published online: April 2, 2014

Age-Adjusted Incidence Ratios for Stroke in Risk Periods Following Zoster

Outcome and Risk Period	No. of Cases	IRa (95% CI)
Stroke (all types)	6584
Risk period after zoster
1–4 wk	90	1.63 (1.32–2.02)
5–12 wk	149	1.42 (1.21–1.68)
13–26 wk	215	1.23 (1.07–1.42)
27–52 wk	303	0.99 (.88–1.12)

---

帯状疱疹後6ヶ月内は卒中リスク増加し、帯状疱疹ワクチンにより、卒中リスク減少も示唆。

---

抗ウィルス薬治療も帯状疱疹後卒中リスク減少と関連する可能性有り。
 ge-Adjusted Incidence Ratios for Stroke in Risk Periods Following Zoster, Stratified by Oral Antiviral Drug Prescriptions

Site of Zoster and Risk Period	Oral Antiviral Prescriptiona		No Oral Antiviral Prescription
	No. of Cases	IRb (95% CI)	No. of Cases	IRb (95% CI)
Zoster (all)	3647		2937
Risk period post zoster
1–4 wk	38	1.23 (.89–1.71)	52	2.14 (1.62–2.84)
5–12 wk	75	1.28 (1.02–1.62)	74	1.61 (1.27–2.03)
13–26 wk	117	1.19 (.99–1.44)	98	1.29 (1.05–1.58)
27–52 wk	184	1.08 (.93–1.25)	119	0.89 (.74–1.07)
Ophthalmic	299		127
Risk period post zoster
1–4 wk	3	1.26 (.40–3.96)	3	3.27 (1.02–10.44)
5–12 wk	12	2.57 (1.43–4.62)	10	5.47 (2.80–10.71)
13–26 wk	12	1.55 (.86–2.79)	3	1.00 (.31–3.18)
27–52 wk	10	0.70 (.37–1.33)	6	1.12 (.48–2.59)
Site unspecified	3337		2789
Risk period post zoster
1–4 wk	35	1.23 (.88–1.73)	49	2.10 (1.58–2.81)
5–12 wk	63	1.17 (.91–1.51)	64	1.45 (1.13–1.87)
13–26 wk	105	1.16 (.96–1.42)	94	1.29 (1.05–1.59)
27–52 wk	172	1.10 (.94–1.29)	113	0.89 (.73–1.07)